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Background: Inﬂ  ammation increases during exacerbations of COPD, but only a few studies 
systematically assessed these changes. Better identiﬁ  cation of these changes will increase our 
knowledge and potentially guide therapy, for instance by helping with quicker distinction of 
bacterially induced exacerbations from other causes.
Aim: To identify which inﬂ  ammatory parameters increase during COPD exacerbations com-
pared to stable disease, and to compare bacterial and non-bacterial exacerbations.
Methods: In 45 COPD patients (37 male/8 female, 21 current smokers, mean age 65, FEV1 
52% predicted, pack years 38) sputum was collected during a stable phase and subsequently 
during an exacerbation.
Results: Sputum total cell counts (9.0 versus 7.9 × 106/mL), eosinophils (0.3 versus 
0.2 × 106/mL), neutrophils (6.1 versus 5.8 × 106/mL), and lymphocytes (0.07 versus 
0.02 × 106/mL) increased signiﬁ  cantly during an exacerbation compared to stable disease. 
A bacterial infection was demonstrated by culture in 8 sputum samples obtained during an 
exacerbation. These exacerbations had signiﬁ  cantly increased sputum total cell and neutrophil 
counts, leukotriene-B4, myeloperoxidase, interleukin-8 and interleukin-6, and tumor necrosis 
factor-α (TNF-α) levels, and were also associated with more systemic inﬂ  ammation compared 
to exacerbations without a bacterial infection. Sputum TNF-α level during an exacerbation had 
the best test characteristics to predict a bacterial infection.
Conclusion: Sputum eosinophil, neutrophil, and lymphocyte counts increase during COPD 
exacerbations. The increase in systemic inﬂ  ammation during exacerbations seems to be limited to 
exacerbations caused by bacterial infections of the lower airways. Sputum TNF-α is a candidate 
marker for predicting airway bacterial infection.
Keywords: chronic obstructive pulmonary disease, exacerbation, inﬂ  ammation, sputum 
induction
Introduction
The frequent occurrence of exacerbations is an important feature of chronic obstructive 
pulmonary disease (COPD). The impact of exacerbations on a patient’s health is large 
since they are remarkably closely linked to quality of life, accelerated lung function 
loss, and to mortality.1,2 There is also a huge impact on society since the direct costs 
to the health care system associated with the management of acute exacerbations of 
COPD are enormous.3 Notwithstanding this, there is still no universally accepted deﬁ  ni-
tion of a COPD exacerbation though several have been proposed.4–7 All deﬁ  nitions of 
exacerbation focus on symptoms, sometimes in combination with infectious etiology 
and/or airway obstruction, but remarkably, none of the deﬁ  nitions make any reference 
to changes or increases in inﬂ  ammation. This is especially relevant since inﬂ  ammation 
is part of the deﬁ  nition of COPD,6 and most clinicians hold the general perception that 
exacerbations are associated with changes in airway inﬂ  ammation.International Journal of COPD 2009:4 102
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There is limited understanding of the causes of 
exacerbations, and, linked to this of the optimal treatment in 
relation to the cause. This has resulted in large international 
differences in the prescription levels of most notably antibiot-
ics, given the lack of sufﬁ  cient guidance to prescribe antibiotics 
or none. This is partially due to the fact that results of sputum 
cultures have quite a delay before test results are known. 
Thus a quicker detection of bacterial infections during COPD 
exacerbations should also lead to improvements in clinical care 
by aiding in the decision whether to start antibiotics. A few 
markers have been proposed, such as C-reactive protein (CRP), 
and procalcitonin,8,9 but none have good test characteristics or 
have gained wide acceptance so far.
The aim of the current study is to identify which inﬂ  am-
matory parameters are increased in induced sputum and in 
blood during COPD exacerbations compared to a stable phase 
of the disease, and speciﬁ  cally to assess which parameters 
change during a bacterial exacerbation. Some of the present 
results have been described in the form of an abstract.10
Methods
Patients with a diagnosis of COPD were included if 
age 40 years, post-bronchodilator forced expiratory ﬂ  ow 
in the ﬁ  rst second (FEV1) 85% predicted and 0.7 L, 
postbronchodilator FEV1/slow inspiratory vital capac-
ity (IVC)  predicted normal (88% predicted in men 
and 89% predicted in women),11 and were current or ex 
smokers. Patients were not allowed to use oral cortico-
steroids, long-acting anticholinergics, beta-blockers, or 
long term oxygen therapy, have a history of asthma, or a 
signiﬁ  cant other disease that could interfere with results of 
the study. The local medical ethics committee approved the 
study. A written informed consent was obtained from all 
patients prior to the study.
Study design
In case inhaled corticosteroids (ICS) were being used at 
inclusion, they were discontinued. Thereafter subjects had 
to be stable for 2 months. At the second visit, 2 months later, 
spirometry was performed followed by sputum induction; these 
measures were used as baseline, stable phase values in the study. 
From the second visit until the end of the randomized treatment 
period, all long-acting beta2-sympaticomimetics were also 
withdrawn. Patients were asked to contact the research doctor, 
who was available around the clock, to report any deteriora-
tion in symptoms for which they would normally contact their 
primary care physician or pulmonologist. An exacerbation was 
deﬁ  ned as a history of increased breathlessness and at least two 
of the following symptoms for 24 hours or more: increased 
cough frequency or severity, sputum volume or purulence, and 
wheeze. When presenting with an exacerbation, patients were 
randomized provided postbronchodilator FEV1 was 70% 
of predicted and PaO2  8.0 kPa. After this, a randomized 
controlled trial followed (data not shown).
Measurements
At each visit, sputum induction, blood sampling, and lung 
function measurements were performed. FEV1 and IVC 
were measured according to the guidelines of the European 
Respiratory Society.12
Health status was measured by the Clinical COPD 
Questionnaire.13
Sputum induction and processing
Sputum was induced by standard methods with modiﬁ  ca-
tions according to Pizzichini.14 Whole sputum samples were 
processed within 120 minutes as described previously.15 
Cytospins were prepared and cell-free supernatant was col-
lected and stored in aliquots at –80 °C pending analyses of 
soluble mediators.
Differential cell counts were counted on May Grün-
wald Giemsa stained cytospins in a blinded fashion.16 Cell 
counts were expressed as percentage of non-squamous cells. 
A sputum sample was considered inadequate when the 
percentage squamous cells was 80%.
The following soluble mediators were measured in sputum 
supernatant by ELISA: leukotriene-B4 (LTB4, Amersham 
Biosciences, UK), eosinophilic cationic protein (ECP, Pharma-
cia, Uppsala, Sweden), myeloperoxidase (MPO, homemade17). 
Albumin in sputum and blood was measured by nephelometry 
(Dade Behring, Leusden, the Netherlands). Sputum interleu-
kin-6 (IL-6), IL-8, tumor necrosis factor-α (TNF-α), monocyte 
chemoattractant protein-1 (MCP-1), and both serum IL-6 and 
TNF-α were measured by xMAP technology (Luminex B.V., 
Oosterhout, the Netherlands), using multiplex immunoassay 
kits obtained from Linco, St Charles, USA.
Bacterial culturing
Spontaneous sputum samples were cultured. A bacterial 
cause of exacerbation was deﬁ  ned by the following features: 
the cultured micro-organisms are potentially pathogenic, 
the growth density in the culture is high (semi quantitative), 
the number of squameous epithelial cells is 25, and the 
number of the leukocytes in the Gram-stained preparation of 
the sputum sample is 15 per high power ﬁ  eld (100 × 10), 
which corresponds with Geckler group 4–6).18International Journal of COPD 2009:4 103
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Sputum cytokine mRNA expression
Messenger ribonucleic acid (mRNA) was harvested 
from 1 million viable non-squamous sputum cells. RNA 
was isolated using a Qiagen RNeasy mini kit (Venlo, The 
Netherlands) and cDNA was synthesized as described.19 
Expression of cytokine mRNA was analyzed by quantitative 
real-time PCR, using the ABI 7900 HT system (Applied 
Biosystems, Nieuwekerk a/d IJssel, The Netherlands). 
The gene expression assays for hem-oxygenase-1 (HO-1), 
TNF-α, chemotactic cytokine ligand5 (CCL5), IL-5, IL-10, 
IL-12, IL-13, transforming growth factor-β (TGF-β), inter-
feron-γ (IFN-γ), and β-2-microglobulin, were obtained from 
Applied Biosystems (Nieuwekerk a/d IJssel, Netherlands). 
Cytokine gene expression was normalized to the expression 
of β-2-microglobulin. The mRNA quantiﬁ  cation is expressed 
in threshold cycle values (Ct-values), which is the number 
of ampliﬁ  cation cycles to reach a detectable mRNA amount. 
Thus lower Ct-values correspond with higher mRNA 
expression.
Blood analyses
Blood differential counts were analyzed by ﬂ  ow cytometry 
(Coulter-STKS, Beckman Coulter, Miami, USA). Serum 
C-Reactive Protein (CRP) and albumin were measured by 
nephelometry (Dade Behring, Leusden, the Netherlands).
Statistical analysis
Data are expressed as medians and inter quartile ranges 
(IQR). Non-normally distributed parameters were normal-
ized by log10 transformation. Stable phase levels of inﬂ  am-
matory parameters were compared to exacerbation levels 
using paired sample t-tests, or Wilcoxon log rank tests. 
Exacerbations with and without a bacterial infection were 
compared with respect to both the cross-sectional values at 
exacerbation and the differences in the percentage change 
of biomarkers from baseline to exacerbation (t-tests or 
Mann-Witney U-test). Using Receiver Operating Curves, 
cut-off points for the biomarkers were adjusted until the 
highest area under the curve was reached. Data were analyzed 
using SPSS version 12.0.2.
Results
We included 114 patients in this study. Some patients did not 
sustain corticosteroid withdrawal, or did not remain stable 
in the run in period (n = 9), other patients did not report an 
exacerbation (n = 26), or were excluded due to an adverse 
event (n = 4), or due to various other reasons (n = 30). The 
remaining 45 patients reporting an exacerbation within the 
study period were analyzed. The baseline characteristics of 
these patients are presented in Table 1. During the exacerba-
tion, patients had a signiﬁ  cantly and clinically relevant poorer 
health status as measured by higher CCQ scores compared to 
the stable phase (median value 2.5 versus 1.7 respectively, 
p  0.01). The minimal clinically important difference of 
the CCQ is 0.4.20
Inﬂ  ammatory indices
Sputum samples were adequate in both the stable phase, 
after ICS withdrawal, and during exacerbation in 41 out of 
45 patients. The cellular differences between the stable phase 
(2 months after ICS withdrawal) and during the exacerbation 
are presented in Table 2. Sputum total cell, eosinophil, neu-
trophil, and lymphocyte counts were signiﬁ  cantly increased 
at exacerbation versus stable disease.
Analyses of mRNA levels in sputum showed a lower 
IL-12a expression at exacerbation compared to stable state 
values (median ct-values 41.5 versus 37.7 respectively; 
p = 0.051). No differences were found in sputum mRNA 
Table 1 Patient characteristics of the patients who had an exacerbation during the trial (n = 45), and of the total study population (n = 114)
Patients with exacerbation Total study population
Male/female 37/8 93/21
Age, yearsa 65 (58–71) 64 (59–71)
Smoked, pack-yearsa 38 (26–49) 40 (27–51)
Smoking status, current/ex 21/24 47/67
Body mass index, kg/m2a 25 (24–28) 26 (24–28)
FEV1, % preda 61 (48–73) 63 (52–73)
FEV1/IVC, % 44 (38–53) 63 (51.7–72.7)
Reversibility, % of preda 8.9 (5.3–11.0) 8.9 (5.5–11.8)
CCQ-scorea 1.7 (1.3–2.1) 1.7 (1.3–2.6)
aMedian (interquartile range).
Abbreviations: n, number; pred, predicted; CCQ, Clinical COPD Questionnaire.International Journal of COPD 2009:4 104
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levels of HO-1, TNF-α, IL-5, CCL5, IL-10, IL-12b, IL-13, 
TGF-β, and INF-γ (data not shown). The sputum protein lev-
els of ECP, MCP-1, and LTB-4, were signiﬁ  cantly increased 
at exacerbation compared to stable state and levels of MPO 
and IL-8 tended to be increased (Table 3).
Systemic inﬂ  ammation during COPD exacerbations was 
increased compared to the stable phase, ie, blood leukocyte 
and neutrophil counts were signiﬁ  cantly increased (Table 2), 
as were serum protein levels of IL-6 (Table 3). There was a 
trend towards an increase in CRP (p = 0.07).
Bacterial cultures
Eight sputum samples for bacterial culture during 
exacerbation of COPD were missing: 5 patients produced 
too small a volume of spontaneous sputum, and 3 samples 
were missing due to logistical problems. Eight of the 
remaining 37 sputum samples were indicative of a bacterial 
infection: 5 with Haemophilus inﬂ  uenzae, 2 with Moraxella 
catarrhalis, and 1 with Streptococcus pneumoniae. These 
patients had a negative culture in stable phase. In stable 
phase, 10 patients produced too small a volume of spontane-
ous sputum and 1 was missing due to logistical problems. 
Two of the remaining 34 samples were indicative of a 
bacterial infection (H. influenzae and combination of 
H. inﬂ  uenzae and M. catarrhalis). These 2 patients had a 
negative culture during exacerbation.
Differences between bacterial 
and non-bacterial exacerbations
Table 4 shows the differences between bacterial and non-
bacterial exacerbations both cross-sectionally at the exac-
erbation visit, and as a change from baseline with stable 
disease to the exacerbation in order to correct for stable 
phase values.
Bacterial exacerbations were accompanied by higher val-
ues for sputum total cell and neutrophil counts, LTB4, MPO, 
IL-8, and TNF-α level than non bacterial exacerbations. In 
serum, bacterial exacerbations were associated with higher 
total leukocytes and neutrophil counts. Additionally, when 
analyzed as the percentage change from baseline to exacerba-
tion, serum CRP and IL-6 levels showed a signiﬁ  cantly larger 
increase when a bacterial exacerbation occurred compared 
to exacerbations without a bacterial infection.
The predictive values of the level of blood CRP, sputum 
TNF-α and sputum MPO for a bacterial cause of the 
exacerbation are presented in Receiver Operating Curves 
(Figure 1). Sputum TNF-α had the best test characteristics.
Discussion
The present study assessed the change in inﬂ  ammation from a 
stable phase of COPD to an out-patient COPD exacerbation. 
Eight patients had a sputum sample indicative of a bacterial 
infection. None of these patients had a positive culture in 
stable phase. Sputum neutrophil, lymphocyte, and eosinophil 
numbers increased during an exacerbation. Furthermore, 
systemic inﬂ  ammation increased during exacerbations as 
assessed by blood total leukocyte and neutrophil counts, and 
serum CRP and IL-6. These biomarkers were particularly 
increased in case of bacterial exacerbations. The level of 
sputum TNF-α during an exacerbation was the best predictor 
of a bacterial airway infection.
Airway inﬂ  ammation during COPD exacerbations has 
been the focus of a few studies but their results have been 
inconsistent.21–26 This inconsistency can be explained by sev-
eral factors. Firstly, it is difﬁ  cult to gain information regarding 
airway inﬂ  ammation during COPD exacerbations. Sputum 
induction by inhaled saline can cause additional broncho-
constriction and analysis of spontaneously produced sputum 
samples yields less cell viability,27 whereas more invasive 
techniques such as bronchoscopy are even more difﬁ  cult to 
Table 2 Cellular inﬂ  ammatory parameters
Stable Exacerbation
Sputum
 Total  cells  × 106/mL 7.9 (2.1–19.2) 9.0 (4.0–29.8)*
  Eosinophil, % 2.7 (0.8–5.8) 2.8 (0.8–4.8)
 Eosinophil  × 106/mL 0.2 (0.1–0.4) 0.3 (0.1–0.7)*
  Neutrophils, % 71.7 (65.3–80.0) 72.0 (62.1–86.1)
 Neutrophils  × 106/mL 5.8 (1.5–13.4) 6.1 (2.1–24.1)*
  Macrophages, % 20.7 (14.5–26.8) 17.7 (10.1–24.9)
 Macrophages  × 106/mL 1.4 (0.5–3.7) 2.1 (0.6–4.1)
  Lymphocytes, % 0.3 (0.0–1.3) 0.8 (0.3–1.3)*
 Lymphocytes  × 106/mL 0.02 (0.00–0.10) 0.07 (0.03–0.20)*
Blood
 Leukocytes  × 109/mL 6.6 (6.0–8.2) 7.5 (5.9–9.1)*
  Eosinophil, % 3.2 (2.2–5.8) 2.9 (1.9–5.8)
 Eosinophil,  × 109/mL 0.2 (0.2–0.3) 0.2 (0.1–0.4)
  Neutrophils, % 61.0 (55.4–65.9) 63.0 (57.2–68.2)
 Neutrophils,  × 109/mL 4.2 (3.5–4.9) 4.6 (3.4–6.1)*
  Monocytes, % 10.1 (8.3–11.0) 8.8 (7.9–10.8)
 Monocytes,  × 109/mL 0.6 (0.5–0.8) 0.7 (0.6–0.8)
  Lymphocytes, % 24.4 (20.2–28.8) 22.9 (20.4–27.1)
 Lymphocytes,  × 109/mL 1.6 (1.4–2.0) 1.7 (1.4–2.0)
Note: 41 of 45 patients had an adequate sample for sputum cell differential analysis 
at both stable phase and exacerbation.
Median (interquartile range). *signiﬁ  cant difference (p  0.05).International Journal of COPD 2009:4 105
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perform during exacerbations. Secondly, the causes of COPD 
exacerbations are heterogeneous. It is possible that well 
known inducing factors such as viruses, bacteria, and air pol-
lution lead to different inﬂ  ammatory patterns.6 Additionally, 
the speciﬁ  c focus of a study may well bias the selection of 
patients, for instance in the case of studies assessing the 
efﬁ  cacy of antibiotics. Thirdly, the use of medication by 
patients with COPD can inﬂ  uence the inﬂ  ammatory pattern, 
as is known with inhaled corticosteroids.28
This study was part of a randomized controlled trial 
studying the anti-inflammatory treatment effects of 
budesonide/formoterol therapy versus prednisolone during 
COPD exacerbations.29 To study these effects without biasing 
effects of maintenance therapy, inhaled corticosteroids 
were withdrawn if used. This study design also allowed 
us to study the change in inﬂ  ammation from stable disease 
prospectively, non-modulated by inhaled corticosteroid 
therapy. The results should therefore be extrapolated only 
to similar patients, ie, not on steroids. Whether the same 
ﬁ  ndings hold true for patients on inhaled corticosteroids 
remains to be established.
As expected, there was an increase in sputum neutrophils 
during COPD exacerbations.23,26,30 The increase in sputum 
neutrophil numbers was accompanied by an increase 
in sputum levels of LTB4 and IL-8, both attractants of 
neutrophils, and the neutrophil degranulation product MPO. 
These changes conﬁ  rm an earlier study of Gompertz et al31 
reporting a decrease in airway inﬂ  ammation from the start 
of a COPD exacerbation to its resolution. These authors also 
reported a change in microvascular leakage as determined 
by the sputum/serum albumin ratio, which we conﬁ  rm in our 
prospective study.
Furthermore, we found an increase of sputum lymphocytes 
during exacerbations. Lymphocytes play an important role in 
the pathogenesis of COPD. They are related to its develop-
ment and progression. Lams et al found that smokers who 
develop COPD have increased CD8+ T-cells in large airways 
compared to asymptomatic smokers.32 Furthermore, there is 
an increase in CD4+ cells in patients with COPD, particularly 
as the disease progresses.33 This increase in lymphocytes has 
been suggested to be caused by chronic immune stimulation 
due to infectious pathogens.34 Not only T-cells, but also 
B-cells are increased in stable COPD.35–37 Although in this 
study we did not succeed in identifying viruses in induced 
sputum samples for an unknown but presumably technical 
reason, we still believe that viral airway infections may con-
tribute in this respect.38, 39 An autoimmune origin has also been 
suggested.35,40,41 Whether part of the increase in lymphocytes 
in our study is of B-cell origin was not evaluated.
This is at least the forth report documenting an increase 
in eosinophil counts during exacerbations.25,30,42 Next to the 
increase in eosinophils, we also found increased sputum 
ECP. ECP has been associated with tissue damage and tissue 
remodelling in in vitro studies.43 This might thus contribute 
Table 3 Inﬂ  ammatory biomarkers
Stable Exacerbation p-value
Sputum
  LTB-4 ng/mL 0.4 (0.2–0.7) 0.5 (0.3–1.1) 0.03
 TNF-α pg/mL 1.6 (1.6–8.7) 4.6 (1.6–31.5) 0.37
  IL-6 pg/mL 287 (183–637) 361 (164–783) 0.24
 IL-8  μg/mL 1.5 (0.9–4.4) 2.0 (1.2–6.3) 0.07
  MCP-1 pg/mL 119 (63–560) 210 (137–385) 0.01
 MPO  μg/mL 9.2 (5.3–31.0) 15.1 (8.4–56.0) 0.08
 ECP  μg/mL 85.4 (49.6–319.5) 187.0 (81.3–295.0) 0.03
Serum
  IL-6 pg/mL 0.4 (0.1–4.0) 0.6 (0.1–9.9) 0.03
 TNF-α pg/mL 4.9 (3.3–6.8) 4.5 (2.6–6.9) 0.90
  sICAM ng/mL 109 (91–129) 118 (105–132) 0.13
  CRP mg/L 3.4 (1.8–8.2) 3.6 (1.5–17.1) 0.07
Sputum/serum
  Albumin ratio 1.7 (0.9–3.5) 2.0 (1.1–3.3) 0.03
Median (interquartile range). Analyzed for differences with paired t-tests.
Abbreviations: LTB4, leukotriene-B4; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IL-8, interleukin-8; MCP-1, monocyte chemoattractant protein-1; MPO, myeloperoxidase; 
ECP, eosinophilic cationic protein; sICAM, soluble intercellular adhesion molecule; CRP, C-reactive protein.International Journal of COPD 2009:4 106
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Table 4a Differences between bacterial and non-bacterial exacerbations (sputum parameters)
Sputum Cross-sectional values at exacerbation Change from stable phase 
to exacerbation (%)
Bacterial 
exacerbation
Non-bacterial 
exacerbation
Bacterial 
exacerbation
Non-bacterial 
exacerbation
total cell × 106 /mL†† 51.1 (21.2–66.6)* 7.60 (2.94–22.9) 269 (44–3183)‡ −5 (−36 to −95)
eosinophil × 106 /mL†† 0.49 (0.22–1.30) 0.29 (0.06–0.79) 134 (−22 to −1460) 51 (−34 to −174)
neutrophil × 106 /mL†† 47.4 (13.2–60.2)* 4.85 (1.91–17.2) 203 (35–760)‡ 4 (−39 to −87)
lymphocyte × 106 /mL‡† 0.22 (0.05–0.56) 0.07 (0.03–0.21) 949 (33–3815) 114 (−31 to −482)
ECP μg/mL†† 247 (139–1001) 187 (96.9–279) 137 (9–222) 50 (−20 to −183)
LTB4 ng/mL‡‡ 1.43 (0.71–2.01)* 0.43 (0.34–0.59) 164 (50–347)‡ 0 (−26 to −54)
MPO μg/mL†† 57.7 (30.4–89.9)* 12.6 (6.29–34.6) 349 (−2 to −955) 7 ( −34 −102)
IL-6 pg/mL†† 680 (267–1251) 325 (153–733) 116 (52–610)‡ −16 (−47 to −77)
IL-8 μg/mL† † 7.78 (3.52–9.90)* 1.74 (0.92–4.47) 149 (0–444) 6 (−23 to −72)
TNF-a pg/mL‡‡ 56.8 (43.3–69.7)* 3.43 (1.60–7.73) 1580 (91–583)‡ 0 (−17 to −110)
MCP-1 pg/mL†† 283 (177–799) 194 (131–360) 141 (11–376) 41 (−32 to −171)
Sputum/serum albumin‡‡ 3.06 (2.44–3.65) 1.99 (1.14–3.11) 51 (15–85) 35 (−21 to −100)
Table 4b Differences between bacterial and non-bacterial exacerbations (blood parameters)
Cross-sectional values at exacerbation Change from stable phase 
to exacerbation (%)
Bacterial 
exacerbation
Non-bacterial 
exacerbation
Bacterial 
exacerbation
Non-bacterial 
exacerbation
Blood/serum
leukocytes × 106/mL†† 8.95 (7.95–10.3)* 6.60 (5.70–8.15) 24 (1–53)‡ 2 (−5 to −18)
neutrophil × 106/mL†† 6.47 (4.87–7.62)* 3.84 (3.34–5.63) 23 (5–69) 4 (−14 to −25)
sICAM μg/mL†‡ 11.2 (10.3–13.9) 12.1 (10.5–13.3) 11 (−5 to −26) 4 (−3 to −13)
CRP mg/L‡‡ 9.08 (4.56–26.2) 2.6 (1.4–15.3) 143 (39–740)‡ 1 (−42 to −87)
IL-6 pg/mL‡‡ 4.86 (1.22–10.0) 0.40 (0.10–10.7) 670 (119 to –2225)‡ 0 (−2 to −126)
TNF-a pg/mL‡† 4.50 (2.33–7.36) 4.60 (2.61–7.00) −7 (−23 to −21) −11 (−21 to −13)
Notes: Data presented as median (IQR). †Tested for differences by T-test; ‡Tested for differences by Mann-Witney-U-test; * p  0.05 for the difference in cross-sectional values 
between bacterial and non bacterial exacerbations; ‡p  0.05 for the difference in percentage change from stable to exacerbation values between bacterial and non-bacterial 
exacerbations.
Abbreviations: LTB4, leukotriene-B4; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IL-8, interleukin-8; MCP-1, monocyte chemo-attractant protein-1; MPO, 
myeloperoxidase; ECP, eosinophilic cationic protein; CRP, C-reactive protein.
to the observed association between exacerbation frequency 
and excess decline in lung function.1 However, not all prior 
studies have found increases in eosinophils during COPD 
exacerbations.22 This difference between our and others’ 
observation of an increase in eosinophils may be simply 
explained by a suppressive effect of the used steroids on 
sputum eosinophils in these studies.28
Neutrophil, and eosinophil sputum cell counts, were 
signiﬁ  cantly increased, but not their percentages. This shows 
that absolute cell counts provide different information about 
inﬂ  ammation than cell percentages. Absolute cell counts reﬂ  ect 
the concentration of these cells and therefore the total load, 
whereas the percentage reﬂ  ects an inﬂ  ammatory pattern. Our 
data point out that there can be an increase in inﬂ  ammation, 
without a signiﬁ  cant change in the inﬂ  ammatory pattern.
Next to increased sputum inﬂ  ammation as proxy of airways 
inﬂ  ammation, we also found increased systemic inﬂ  ammation 
as demonstrated by increased number of blood total leukocytes, 
neutrophils, IL-6, and a trend in CRP during exacerbations. 
This conﬁ  rms an earlier report of increased systemic inﬂ  am-
mation (increased serum IL-6 and CRP) during COPD exac-
erbations.44,45 In 22% of our sputum samples the exacerbation 
was associated with a bacterial infection. These exacerbations 
showed a higher increase of total cell and neutrophil counts, 
IL-6, TNF-α levels in sputum, and leukocyte and neutrophil 
counts, CRP, and IL-6 levels in blood. This relationship of International Journal of COPD 2009:4 107
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Figure 1 Receiver operating characteristic curves for distinguishing a bacterial 
cause of exacerbations with inﬂ  ammatory markers. On the curve, several biomarker 
concentration levels are presented, which provides an indication for optimal cut-off 
points and their corresponding predictive values.
a) sputum tumor necrosis factor-α (TNF-α), b) blood C-reactive protein (CRP), 
c) sputum myeloperoxidase (MPO).
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a)  higher sputum and systemic inﬂ  ammation in the presence of 
a bacterial pathogen in sputum has been reported in earlier 
studies,26,44 though not all studies have found this relationship.21 
However, these studies did not investigate whether these high 
levels were already present in stable state,26,44 or, as we now 
show, indeed reﬂ  ected an increase that occurs with a bacterial 
infection. Our data show that some of the biomarkers that are 
increased in an exacerbation actually only change if the speciﬁ  c 
exacerbation is induced by a bacterial infection.
Serum CRP has been investigated as a marker to identify 
exacerbations in one study.8 The predictive value of serum 
CRP alone was limited in that study, and use of the com-
bination of the CRP level with a symptom of exacerbation 
was proposed to improve the predictive value of CRP. Our 
study shows that CRP is much more increased in bacterial 
exacerbations. We believe this underlines the limitations of 
CRP as a general biomarker of COPD exacerbations.
It would be of clinical use if clinicians would have bio-
markers with cut-off points to differentiate which patient 
has a bacterial airway infection. If one would know from a 
rapidly available biomarker whether there is a high chance 
of a bacterial infection, this would improve the efﬁ  ciency of 
use of antibiotic treatment. Our study population had mild 
to moderate COPD and is not large enough to provide ﬁ  rm 
data on such cut-off points, and we investigated exacerba-
tions that did not require hospitalization. Nevertheless, we 
do present the receiver operating charateristic curves to offer 
reference and directions for future assessment of ﬁ  rm cut-off 
points. From our preliminary analyses, sputum TNF-α seems 
to be a good candidate biomarker in future studies. Sputum 
TNF-α levels were only increased in patients with a bacterial 
exacerbation, and not in patients with a non-bacterial exacer-
bation. Since the majority of patients did not have a bacterial 
exacerbation, the change in sputum TNF-α levels for the 
total group from stable to exacerbation was not signiﬁ  cant 
(Table 3). This ﬁ  nding is supported by a study by Sethi et al 
which reports signiﬁ  cantly increased sputum TNF-α levels 
in exacerbations with new bacterial strains.46 We do not 
have data on changes in strains: all patients with an bacterial 
exacerbation had negative cultures in stable phase.
In summary, this study showed an increase in neutro-
philic, eosinophilic, and lymphocytic airway inﬂ  ammation 
from a stable phase of disease to an exacerbation in out-
patient COPD patients withdrawn from inhaled corticoste-
roids. In addition, systemic airway inﬂ  ammation increased 
during exacerbations and of interest, this was limited to 
exacerbations with bacterial infections. Some of the bio-
markers, speciﬁ  cally sputum LTB4, MPO, IL-6, TNF-α, International Journal of COPD 2009:4 108
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and serum CRP and IL-6, which are commonly associated 
with exacerbations, are increased during bacterial exacerba-
tions, but little or not increased at all during non-bacterial 
exacerbations. Though our group of patients was too small 
to draw ﬁ  rm conclusions, the data lend support to further 
investigation of whether these inﬂ  ammatory parameters, and 
speciﬁ  cally TNF-α, provide a useful tool for identiﬁ  cation 
of a bacterial infection in COPD.
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